Virpax Pharmaceuticals said that nasal delivery of its VRP324 dry powder cannabidiol in a rodent model produced high concentrations of CBD in the brain. In September 2021, Virpax announced that it had licensed Nanomerics’s molecular envelope technology (MET) for use with VRP324 and that Nanomerics was conducting preclinical studies. Virpax, which is developing the … [Read more...] about Virpax reports successful nose-to-brain delivery in a study of VRP324 dry powder CBD in a rodent model
News
Firebrick Pharma initiates Phase 2 trial of Nasodine povidone-iodine nasal spray for COVID-19
Australian pharmaceutical company Firebrick Pharma has announced the initiation of a Phase 2 trial of its Nasodine povidone-iodine nasal spray for the reduction of viral shedding in patients with COVID-19. According to Firebrick, a 2001 pilot study with 6 COVID-19 patients demonstrated that a single dose of Nasodine reduced viral shedding by almost 80% one hour post … [Read more...] about Firebrick Pharma initiates Phase 2 trial of Nasodine povidone-iodine nasal spray for COVID-19
Zambon’s CMS I-neb inhaled colistimethate sodium gets Breakthrough Therapy designation
The FDA has granted Breakthrough Therapy designation to Zambon's CMS I-neb colistimethate sodium for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult patients with chronic P. aeruginosa lung infections, the company said. The FDA had previously granted QIDP and Fast Track designations to the colistimethate sodium powder, which is delivered as a … [Read more...] about Zambon’s CMS I-neb inhaled colistimethate sodium gets Breakthrough Therapy designation
Inke to triple inhalation API manufacturing capacity
Inhalation API manufacturer Inke has announced a €9 million expansion of its manufacturing facility in Castellbisbal, Barcelona, Spain "to reinforce focus on inhalation micronized APIs," with the aim of tripling its production capacity by 2024. According to Inke, the site currently makes 34 APIs for pharma companies in the US, Europe, Turkey, Japan, China, and Korea, … [Read more...] about Inke to triple inhalation API manufacturing capacity
Rensselaer and Albany Medical College get funding for development of pentosan polysulfate nasal spray against COVID-19
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College will use a $500,000 grant from the New York State Biodefense Commercialization Fund for early development of a pentosan polysulfate (PPS) nasal spray for the prevention of respiratory infections, including COVID-19. PPS is currently approved in the US as an oral treatment for bladder … [Read more...] about Rensselaer and Albany Medical College get funding for development of pentosan polysulfate nasal spray against COVID-19
Positive Phase 1 results for TFF Pharmaceuticals’ dry powder niclosamide
TFF Pharmaceuticals announced that a Phase 1 SAD/MAD study of its dry powder niclosamide found that inhalation of the formulation was well tolerated at all doses evaluated and that data from the study suggest moving into a Phase 2 study with a twice daily 6 mg dose. The company, which recently said that the dry powder niclosamide completely inhibited the Omicron … [Read more...] about Positive Phase 1 results for TFF Pharmaceuticals’ dry powder niclosamide
SK Bioscience partners with IAVI and University of Washington on development of binder protein nasal spray against COVID-19
SK Bioscience announced that it has partnered with nonprofit research organization IAVI on development of an antiviral nasal spray based on a protein developed by David Baker at the University of Washington. The company noted that it will get $2.2 million out of a grant by the Bill & Melinda Gates Foundation to IAVI for the project. The Gates Foundation also … [Read more...] about SK Bioscience partners with IAVI and University of Washington on development of binder protein nasal spray against COVID-19
Intranasal minibinder proteins effective against SARS-CoV-2 in preclinical studies
Researchers from Northwestern University, the University of Washington, and Washington University at St. Louis have published data demonstrating that select miniproteins neutralized SARS-CoV-2 better than mAbs currently in use for the treatment of COVID-19. The multivalent minibinder demonstrated potent activity against all variants of the virus tested, including … [Read more...] about Intranasal minibinder proteins effective against SARS-CoV-2 in preclinical studies
Receptor Life Sciences raises $9.7 million for development of RLS103 dry powder CBD
Receptor Life Sciences said that it has closed a $9.7 million Series A-1 financing and will use the proceeds for clinical development of its RLS103 cannabidiol DPI. RLS103 is based on MannKind Corporation's Technosphere particle engineering technology, which Receptor licensed for use with its cannabinoid products in 2016. The company is developing the inhaled CBD … [Read more...] about Receptor Life Sciences raises $9.7 million for development of RLS103 dry powder CBD
Upperton Pharma Solutions launches nasal delivery development platform
UK-based CDMO Upperton Pharma Solutions has launched a nasal delivery development platform called UpperNose, the company said. The UpperNose services include pre-formulation analyses, dosage form selection, and formulation and process development through to clinical trial manufacturing. Upperton Chief Scientific Officer Richard Johnson said, "The delivery of … [Read more...] about Upperton Pharma Solutions launches nasal delivery development platform